Pyxis Oncology Reviews

Thank you very much for your review. We appreciate your feedback regarding our positive work environment and the team of PYXS employees! We are sorry that your experience wasn't as positive as we would have hoped. Our team remains laser-focused on the clinical development of our lead therapeutic candidate, micvotabart pelidotin (MICVO), a first-in-concept antibody-drug conjugate (ADC), to help improve the lives of patients with cancer. If you have specific concerns or ideas, you’d be open to sharing in more detail, we’d welcome the opportunity to learn from your experience.

Thank you for taking the time to share your feedback. We understand that working in a fast-moving biotech environment, especially in an early-stage company where uncertainty is part of the journey, inherently involves risk, and while clinical development can be unpredictable, we stand behind the integrity of our data and the rigor of our science. We’re proud of the dedication and talent of our team, and we remain laser-focused on the clinical development of our lead therapeutic candidate, micvotabart pelidotin (MICVO), a first-in-concept antibody-drug conjugate (ADC). If you have specific concerns or ideas you’d be open to sharing in more detail, we’d welcome the opportunity to learn from your experience.